December 22, 2016 6:14pm
Lacks of volume as a lot of traders and institutions have already made their “moves" for the year.
The stem, cell, gene and regenerative therapy (SCG&RT) sector opened negative, stayed negative at the mid-day and closed negative.
I am right more often than not and investors have always been able to count on ME for return on investment (ROI); start thinking return on speculation!
Pre-open indication’s tally: 2 hits (ONVO and VCEL) and 2 miss (BLCM, JUNO and VSTM)
There are two things that investors need - interpretation of news and translation of market realities concerning the SCG&RT sector to corroborate share pricing.
I answer one question; in which company should investors put, keep and commit their money!
I say today what others won't, so you can do what others can't!
U.S. equities fell on Thursday, with consumer discretionary lagging, as investors digested a series of economic data, while the Dow Jones industrial average failed to reach a key psychological level.
The NASDAQ closed DOWN -24.01 or -0.44% to 5,447.42 and the DOW closed DOWN -23.08 or -0.12% to 19,918.88.
A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:
- The open was negative with an A/DL of 16/21 and 6 flats;
- The mid-day stayed negative with an A/DL of 9/30 and 4 flats;
- The closing bell continued negative with A/DL of 10/30 and 3 flats;
Henry’omics:
The stem, cell, gene and regenerative therapy (SCG&RT) sector opened negative, stayed negative at the mid-day and closed negative.
- From this morning’s investor’s letter, “if you want to trade pre and post-holiday in the sector … Think cash and per share positions. MY rousing theme until years-end is who are and will be the “come-back kids “in 2017.”
Reiterating, “As the Hanukah and Christmas holidays approach expect trading volumes to DROP significantly, which may lead to volatile swings within the market.
The iShares Russell 2000 (IWM) indicated a negative -0.49% in the pre- open and closed DOWN -0.86%; the iShares NASDAQ Biotechnology (IBB) did NOT indicate in the pre-open and closed DOWN -0.40%.
The CBOE Volatility Index (VIX), widely considered the best gauge of fear in the market, traded lower near 11.5.
Today’s 3 biggest $ gainers included:
- Northwest Bio (NWBO) +$0.22;
- Opexa (OPXA) +0.19;
- VistaGen (VTGN) +$0.17
Today’s 3 biggest $ losers of the session were:
- Kite Pharma (KITE) -$2.80 after Wednesday’s -$2.49 after Tuesday’s +$0.75 after Monday’s -$1.13 after Friday’s+$2.49 after Thursday’s +$1.64 after last Wednesday’s +$1.02;
- Spark Therapeutics (ONCE) -$2.56 after Wednesday’s-$2.73 after Tuesday’s +$1.74 after Monday’s -$2.13;
- bluebird bio (BLUE) -$1.75 after Wednesday’s -$2.85;
The downside trend reflects a pricing trend range of:
- Thursday’s decliners ranged from -0.39% <KOOL> to -10.71% <SGMO> in 30 equities;
- Wednesday’s decliners ranged from – 0.20% <MESO> to –7.22% <KOOL) in 31 equities;
- Tuesday’s decliners ranged from -0.32% <CUR> to -28.35% <NWBO> in 15 equities;
- Monday’s decliners ranged from -14.69% <NWBO> to -0.48% <RGNX> in 20 equities;
- Friday’s decliners ranged from -0.07% <BLUE> to -19.36% <NWBO> in 26 equities;
- Last Thursday’s decliners ranged from -0.11% <MDXG> to -15.06% <NWBO>in 19 equities;
The upside shows a pricing trend range of:
- Thursday’s gainers ranged from +0.36% <FATE> to +39.31% <NWBO> in 10 equities;
- Wednesday’s gainers ranged from +0.28% <VTGN> to +1.68% <CAPR> in 9 equities;
- Tuesday’s gainers ranged from +0.07% <BLUE> to +9.52 <ADVM>in 25 equities;
- Monday’s gainers ranged from +0.27% <ONVO> to +16.24% <CUR> in 22 equities:
- Friday’s gainers ranged from +0.09% <ONCE> to +10.42% <CYTX> in 14 equities;
- Last Thursday’s gainers ranged from +0.28% <VTGN> to +14.22% <BSTG> in 22 equities;
Wrap-up: anybody can read a paragraph … review the percentage changes per day in the week of the decliners and advancers while …
- Thursday’s 10 gainers compared to Wednesday’s 9 having slipped after Tuesday’s 25 following Monday’s 22 compared Friday’s 26
- Thursday’s 30 decliners compared to Wednesday’s 31 which doubled after Tuesday’s 15 following Monday’s 20 compared to Friday’s 14 …
Pre-open indication’s tally: 2 hits (ONVO and VCEL) and 2 miss (BLCM, JUNO and VSTM)
- Bellicum Pharmaceuticals (BLCM) closed DOWN -$0.3 – miss;
- Juno Therapeutics (JUNO) closed DOWN -$0.12 – miss;
- Organovo (ONVO) closed UP +$0.02 – hit;
- Vericel (VCEL) VCEL) closed UP +$0.00 – hit;
- Verastem (VSTM) closed DOWN - $0.01 – miss;
Percentage (%) decliners:
- Sangamo (SGMO) -10.77%;
- Brainstorm (BCLI) -7.75% after Wednesday’s +0.74% after Tuesday’s -6.60% after Monday’s +7.87% after Friday’s +7.06%;
- Regenxbio (RGNX) -7.42% after Wednesday’s -5.33%;
- Capricor (CAPR) -5.88% after Wednesday’s +1.68%;
Percentage (%) advancers:
- Opexa (OPXA) +21.03%;
- VistaGen (VTGN) +4.83%;
- Mesoblast (MESO) +2.79%;
- Caladrius Biosciences (CLBS) +2.28% after Wednesday’s -5.83%;
- BioLife Solutions (BLFS) +1.89%
Flat:
- Applied Genetic Technologies (AGTC) at $9.50;
- Vericel (VCEL) at $2.90;
- ReNeuron (RENE.L) at $2.625
Review my fear gauge or the CBOE Volatility Index (VIX):
· Thursday traded near 11.5;
· Wednesday traded near 11.3;
· Tuesday traded near 11.5;
· Monday traded near 12;
· Friday traded near 12.2;
· Last Thursday traded near 12.7;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
